Summary
Xeomin Aesthetic
Description
Xeomin Aesthetic is a company that provides a uniquely purified treatment for frown lines between the eyebrows. Their product, Xeomin, is a smart toxin with a double filtered formula that removes unnecessary proteins, providing smoother frown lines tre...
Strengths
- Xeomin Aesthetic has a strong market share in their industry
Weaknesses
- Revenue generated per employee is less than the industry average
Annual Revenue
Xeomin Aesthetic's annual revenue
$5588000
Based on Kona Equity data
-
Revenue per employee
$192690
Employee Count
29 employees
G Score - 1
The G Score is an eight-point scale where firms are given a score of 1 for each of the criteria that they pass. The G score compares a company against the industry median to find those that are healthy and growing.
- G1 Revenue is greater than the industry median.
Location
Unlock unlimited leads
Similar Companies
Key Information
- Name: Xeomin Aesthetic
- Category: Pharmaceuticals
- Industry: Medical spa
- SIC: 28; 283
- NAICS: 32; 325
See similar companies
-
By City Raleigh Small Medical spa in Raleigh Mid-size Medical spa in Raleigh Pharmaceuticals in Raleigh Small Pharmaceuticals in Raleigh Mid-size Pharmaceuticals in Raleigh
-
By State NC Small companies in NC Pharmaceuticals in NC Small Pharmaceuticals in NC Mid-size Pharmaceuticals in NC Small Medical spa in NC Mid-size Medical spa in NC
-
By Category Pharmaceuticals Small Pharmaceuticals Mid-size Pharmaceuticals
-
By Industry Medical spa Small Medical spa Mid-size Medical spa Pharmaceuticals and Medical spa
-
Firmographic data G Score of 1 SIC: 28 SIC: 283 NAICS: 32 NAICS: 325 #Manufacturing #Pharmaceuticals
Frequently Asked Questions
Xeomin Aesthetic's headquarters are located at 6501 Six Forks Rd Raleigh, NC 27615.
Xeomin Aesthetic's official website is xeominaesthetic.com
Xeomin Aesthetic's annual revenue is $5.6 M.
Xeomin Aesthetic's SIC: 28; 283
Xeomin Aesthetic's NAICS: 32; 325.
Xeomin Aesthetic has 29 employees
Xeomin Aesthetic is in the industry of Pharmaceuticals.